secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001104659-25-006544
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sirexatamab + chemo/bev shows 35% ORR in CRC (vs 23% control); gastric trial fails to advance to Phase 3
--------------------------------------------------------------------------------

- Part B DeFianCe (n=188): sirexatamab arm ORR 35% vs control 23%; DCR 86% vs 84%.
- Left-sided tumors ORR 38% (experimental) vs 25% (control); DKK1-high upper quartile ORR 48% vs 11%.
- PFS not yet mature; 82 patients still on study. Leap plans registrational Phase 3 in CRC subject to regulatory discussions.
- Part C DisTinGuish gastric: no clear positive signal; primary PFS endpoints will be negative; no Phase 3 plans for gastric.
- Gastric study showed high discordance between investigator and BICR; sirexatamab combo well-tolerated in both studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925006544/0001104659-25-006544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465925006544/tm254560d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-006544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer